J. Bramstedt

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

A. Kribben, J. Gaedeke, T. Westhoff, 2020, Blood advances.

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

Ulrich C. Klostermeier, G. Deuschl, M. Manns, 2012, BMJ : British Medical Journal.

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry.

A. Kribben, U. Panzer, P. Gerke, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.

A. Kribben, J. Gaedeke, T. Westhoff, 2020, Blood advances.

[Cannabinoid hyperemesis syndrome inducing acute prerenal failure and electrolyte disturbance].

R. Dissmann, J. Bramstedt, 2011, Deutsche medizinische Wochenschrift.

Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.

A. Kribben, K. Schulmann, J. Gaedeke, 2022, Journal of thrombosis and haemostasis : JTH.